G. Getz

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets

This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

Novel mechanism of MYC deregulation in Multiple Myeloma

The paper identifies a new epigenetic mechanism of MYC deregulation in multiple myeloma through enhancer accessibility and transcription factor binding, independent of translocations or amplifications.

Latent human herpesvirus 6 is reactivated in chimeric antigen receptor T cells

The paper identifies HHV-6 reactivation in CAR T cells using single-cell sequencing and links it to clinical neurotoxicity observed in patients.

High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1

The paper identifies five lung adenocarcinoma expression subtypes using consensus hierarchical clustering and finds subtype-specific dependencies on MET, CDK4, CDK6, and PD-L1, which could guide targeted therapies.

Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes

This study identifies six genetic subtypes of smoldering multiple myeloma associated with distinct clinical outcomes and progression risks.

Single-nucleus cross-tissue molecular reference maps to decipher disease gene function

The paper develops a cross-tissue single-nucleus RNA-seq atlas to identify cell types and gene functions in health and disease.

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

This study characterizes intra-tumor heterogeneity across 2,658 human cancer genomes, identifying subclonal mutations and evolutionary patterns across 38 cancer types.

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer

The paper identifies thousands of novel unannotated proteins in cancer that contribute to the MHC I immunopeptidome, expanding potential targets for immunotherapy.

The Repertoire of Mutational Signatures in Human Cancer

The paper characterizes 49 mutational signatures in human cancer using a large dataset of somatic mutations, revealing associations with exposures and DNA repair mechanisms and identifying signatures of unknown origin.

A deep learning system can accurately classify primary and metastatic cancers based on patterns of passenger mutations

This paper develops a deep learning classifier using whole genome sequencing data to distinguish cancer types and identify metastatic origins.

WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers

The paper identifies WRN helicase as a synthetic lethal target in microsatellite unstable cancers through CRISPR/Cas9 and RNAi screens, showing its essentiality in MSI cell lines.

The evolutionary history of 2,658 cancers

This study uses whole-genome sequencing of cancer samples to reconstruct the evolutionary history of 39 cancer types, identifying early and late-stage mutational patterns and driver genes.

Pathway and network analysis of more than 2,500 whole cancer genomes

The paper analyzes non-coding mutations across 2,583 cancer genomes to identify genes and pathways affected, finding clusters of interacting proteins and insights into cancer mechanisms.

Expanding discovery from cancer genomes by integrating protein network analyses with in vivo tumorigenesis assays

The paper develops a method to identify new cancer genes by integrating protein network analysis with in vivo tumorigenesis assays, finding 62 new candidates and validating two in patient data.